胶质瘤中BRAFV600突变患病率及BRAFV600突变阳性胶质瘤患者使用BRAF抑制剂的情况:系统综述
该系统综述基于182篇文献的13682例患者分析胶质瘤BRAFV600突变总体患病率及BRAF抑制剂治疗反应。BRAFV600在上皮样胶质母细胞瘤中患病率最高(69%,95%CI 45-89%),多形性黄色星形细胞瘤为56%(48-64%),在毛细胞型星形细胞瘤等中较低(3%,95%CI 2-5%)。共分析130篇文献中394例接受BRAF抑制剂治疗的V600突变胶质瘤患者,不同级别和年龄组的完全缓解、部分缓解、疾病稳定和疾病进展情况各异。
要点
- BRAFV600在上皮样胶质母细胞瘤中患病率为69%(95%CI 45-89%),多形性黄色星形细胞瘤为56%(48-64%),间变性多形性黄色星形细胞瘤为38%(23-54%)。
- 节细胞胶质瘤患病率为40%(33-46%),间变性节细胞胶质瘤为46%(18-76%),星形母细胞瘤为24%(8-43%)。
- 儿童低级别胶质瘤接受BRAF抑制剂后部分缓解率为41.1%(53/129),完全缓解率为3.1%(4/129)。
核心结论
- BRAFV600患病率在上皮样胶质母细胞瘤、多形性黄色星形细胞瘤、间变性多形性黄色星形细胞瘤、节细胞胶质瘤和间变性节细胞胶质瘤中最高,在星形母细胞瘤、促纤维增生性婴儿星形细胞瘤、室管膜下巨细胞星形细胞瘤、胚胎发育不良性神经上皮肿瘤、弥漫性星形细胞瘤和毛细胞型星形细胞瘤中较低。
- 该数据为V600突变胶质瘤中BRAF抑制剂的辅助临床试验提供了依据。
研究设计与样本
- 系统综述,分析182篇文献中13682例患者胶质瘤BRAFV600突变总体患病率。
- 回顾130篇文献中394例接受BRAF抑制剂治疗的V600突变胶质瘤患者的治疗反应。
主要发现
- 上皮样胶质母细胞瘤BRAFV600患病率为69%(95%CI 45-89%),多形性黄色星形细胞瘤为56%(95%CI 48-64%),间变性多形性黄色星形细胞瘤为38%(95%CI 23-54%)。
- 节细胞胶质瘤患病率为40%(95%CI 33-46%),间变性节细胞胶质瘤为46%(95%CI 18-76%),星形母细胞瘤为24%(95%CI 8-43%)。
- 促纤维增生性婴儿星形细胞瘤患病率为16%(95%CI 0-57%),室管膜下巨细胞星形细胞瘤为8%(95%CI 0-37%),胚胎发育不良性神经上皮肿瘤为3%(95%CI 0-11%),弥漫性星形细胞瘤为3%(95%CI 0-9%),毛细胞型星形细胞瘤为3%(95%CI 2-5%)。
- 129例儿童低级别胶质瘤中,完全缓解4例(3.1%),部分缓解53例(41.1%),疾病稳定64例(49.6%),疾病进展8例(6.2%)。
- 25例儿童高级别胶质瘤中,完全缓解4例(16.0%),部分缓解10例(40.0%),疾病稳定4例(16.0%),疾病进展7例(28.0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detailed prevalence estimates of BRAFV600 mutations and BRAF inhibitor (BRAFi) treatment responses in V600-mutant glioma will inform trial development. METHODS: Our systematic review analyzed overall prevalence of BRAFV600 mutations in glioma and BRAFi treatment response. RESULTS: Based on 13 682 patients in 182 publications, the prevalence of BRAFV600 in epithelioid glioblastoma (eGBM) was 69% [95% CI: 45-89%]; pleomorphic xanthoastrocytoma (PXA): 56% [48-64%] anaplastic pleomorphic xanthoastrocytoma (aPXA): 38% [23-54%], ganglioglioma (GG): 40% [33-46%], and anaplastic ganglioglioma (aGG): 46% [18-76%]. Prevalence in astroblastoma was 24% [8-43%], desmoplastic infantile astrocytoma (DIA): 16% [0-57%], subependymal giant cell astrocytoma (SEGA): 8% [0-37%], dysembryoplastic neuroepithelial tumor (DNET): 3% [0-11%], diffuse astrocytoma (DA): 3% [0-9%], and pilocytic astrocytoma (PA): 3% [2-5%]. We reviewed 394 V600-mutant gliomas treated with BRAFi from 130 publications. One hundred and twenty-nine pediatric low-grade gliomas showed 4 (3.1%) complete response (CR); 53 (41.1%) partial response (PR); 64 (49.6%) stable disease (SD) and 8 (6.2%) progressive disease (PD). 25 pediatric high-grade gliomas showed CR; PR; SD; PD in 4 (16.0%); 10 (40.0%), 4 (16.0%); and 7 (28.0%) respectively. Thirty-nine adult low-grade gliomas showed CR; PR; SD; PD of 4 (10.3%); 17 (43.6%); 16 (41.0%) and 2 (5.1%) respectively. Ninety-seven adult high-grade gliomas showed CR; PR; SD; PD of 6 (6.2%); 31 (32.0%); 27 (27.8%); and 33 (34.0%) respectively. CONCLUSIONS: BRAFV600 prevalence is highest in eGBM, PXA, aPXA, GG, aGG, and lower in astroblastoma, DIA, SEGA, DNET, DA, and PA. Our data provide the rationale for adjuvant clinical trials of BRAFi in V600-mutant glioma.
引用
- Andrews LJ, Thornton ZA, Saincher SS, et al. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol. 2022. PMID: 34718782. doi:10.1093/neuonc/noab247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。